Belantamab mafodotin
|
Abstract Name |
Presenter |
Presentation Details |
|
No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM) |
D. Lowther |
Oral presentation, #248 |
|
Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial |
A. Nooka |
Poster presentation, #3246 |
|
Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review |
M. Hanna |
Online publication |
|
Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies |
N. Boytsov |
Online publication |
Momelotinib
|
Abstract Name |
Presenter |
Presentation Details |
|
Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor |
A. T. Gerds |
Oral presentation, #627 |
|
Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum |
S. Verstovsek |
Poster presentation, #3028 |
|
Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib |
R. A. Mesa |
Poster presentation, #1733 |
|
The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study |
R. A. Mesa |
Poster presentation, #4351 |
|
Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib |
S. Oh |
Oral presentation, #337 |
|
Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs) |
S. Verstovsek |
Poster presentation, #4348 |
|
The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States |
A. T. Gerds |
Poster presentation, #1729 |
Pipeline
|
Abstract Name |
Presenter |
Presentation Details |
|
STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples |
M. Adam |
Online publication |
Real-world outcomes
|
Abstract Name |
Presenter |
Presentation Details |
|
Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment |
R. Popat |
Poster presentation, #3208 |
|
Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study |
J. Richter |
Poster presentation, #1891 |
|
Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study |
M. Hultcrantz |
Poster presentation, #4549 |
|
Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study |
M. Roussel |
Poster presentation, #1856 |
|
The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World |
A. Suvannasankha |
Online publication |
|
Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe |
M. Lehne |
Online publication |
Full list of investigator-sponsored studies and supported collaborative studies at ASH:
Belantamab mafodotin
|
Abstract Name |
Presenter |
Presentation Details |
|
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma |
E. Terpos |
Poster presentation, #1920 |
|
Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial |
E. Terpos |
Poster presentation, #3234 |
|
Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma |
S. Trudel |
Poster presentation, #3248 |
|
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort |
J. Rubia |
Poster presentation, #1881 |
|
Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial |
V. Gonzalez-Calle |
Poster presentation, #3241 |
|
Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network |
E. Kastritis |
Poster presentation, #3244 |
|
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience |
M. Hultcrantz |
Poster presentation, #3225 |
|
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma |
E. Terpos |
Online publication |
|
Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission |
A. Cohen |
Online publication |
